| Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer CM Rudin, S Durinck, EW Stawiski, JT Poirier, Z Modrusan, DS Shames, ... Nature genetics 44 (10), 1111-1116, 2012 | 1154 | 2012 |
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ... Nature Reviews Cancer 19 (5), 289-297, 2019 | 1033 | 2019 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 618 | 2015 |
| A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo LR Saunders, AJ Bankovich, WC Anderson, MA Aujay, S Bheddah, ... Science translational medicine 7 (302), 302ra136-302ra136, 2015 | 608 | 2015 |
| Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis R Romero, VI Sayin, SM Davidson, MR Bauer, SX Singh, SE LeBoeuf, ... Nature medicine 23 (11), 1362-1368, 2017 | 607 | 2017 |
| Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis EE Gardner, BH Lok, VE Schneeberger, P Desmeules, LA Miles, ... Cancer cell 31 (2), 286-299, 2017 | 481 | 2017 |
| Unravelling the biology of SCLC: implications for therapy JK Sabari, BH Lok, JH Laird, JT Poirier, CM Rudin Nature reviews Clinical oncology 14 (9), 549-561, 2017 | 474 | 2017 |
| CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer K Weiskopf, NS Jahchan, PJ Schnorr, S Cristea, AM Ring, RL Maute, ... The Journal of clinical investigation 126 (7), 2610-2620, 2016 | 441 | 2016 |
| Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma–like and non–small cell carcinoma–like subsets N Rekhtman, MC Pietanza, MD Hellmann, J Naidoo, A Arora, H Won, ... Clinical Cancer Research 22 (14), 3618-3629, 2016 | 439 | 2016 |
| A combinatorial strategy for treating KRAS-mutant lung cancer E Manchado, S Weissmueller, JP Morris, CC Chen, R Wullenkord, ... Nature 534 (7609), 647-651, 2016 | 439 | 2016 |
| Regenerative lineages and immune-mediated pruning in lung cancer metastasis AM Laughney, J Hu, NR Campbell, SF Bakhoum, M Setty, VP Lavallée, ... Nature medicine 26 (2), 259-269, 2020 | 365 | 2020 |
| Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks WM Schneider, JM Luna, HH Hoffmann, FJ Sánchez-Rivera, AA Leal, ... Cell 184 (1), 120-132. e14, 2021 | 362 | 2021 |
| SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization MK Baine, MS Hsieh, WV Lai, JV Egger, AA Jungbluth, Y Daneshbod, ... Journal of Thoracic Oncology 15 (12), 1823-1835, 2020 | 362 | 2020 |
| NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination M Ruscetti, J Leibold, MJ Bott, M Fennell, A Kulick, NR Salgado, CC Chen, ... Science 362 (6421), 1416-1422, 2018 | 339 | 2018 |
| PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer BH Lok, EE Gardner, VE Schneeberger, A Ni, P Desmeules, N Rekhtman, ... Clinical Cancer Research 23 (2), 523-535, 2017 | 330 | 2017 |
| Emergence of a high-plasticity cell state during lung cancer evolution ND Marjanovic, M Hofree, JE Chan, D Canner, K Wu, M Trakala, ... Cancer cell 38 (2), 229-246. e13, 2020 | 313 | 2020 |
| Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer JM Chan, A Quintanal-Villalonga, VR Gao, Y Xie, V Allaj, O Chaudhary, ... Cancer cell 39 (11), 1479-1496. e18, 2021 | 274 | 2021 |
| DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2 JT Poirier, EE Gardner, N Connis, AL Moreira, E De Stanchina, CL Hann, ... Oncogene 34 (48), 5869-5878, 2015 | 246 | 2015 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 234 | 2020 |
| ONECUT2 is a driver of neuroendocrine prostate cancer H Guo, X Ci, M Ahmed, JT Hua, F Soares, D Lin, L Puca, A Vosoughi, ... Nature communications 10 (1), 278, 2019 | 226 | 2019 |